How do the side effects of venlafaxine compare with those of other selective serotonin reuptake inhibitors (SSRIs)?

Venlafaxine Side Effects Compared to SSRIs

Venlafaxine has a significantly higher incidence of nausea, vomiting, and discontinuation due to adverse events compared to SSRIs, and carries additional cardiovascular risks that SSRIs generally do not. 1

Common Side Effects Profile

While venlafaxine shares many common side effects with SSRIs (constipation, diarrhea, dizziness, headache, insomnia, sexual dysfunction, and somnolence), there are important differences in frequency and severity 1:

Gastrointestinal Effects

• Venlafaxine causes notably higher rates of nausea and vomiting than other SSRIs 1
• Nausea and vomiting are the most common reasons for treatment discontinuation with venlafaxine 1, 2
• In dose-comparison trials, nausea occurred in 58% of patients on venlafaxine 375 mg/day versus 14.1% on placebo, demonstrating clear dose-dependency 2

Discontinuation Rates

• Venlafaxine has significantly higher discontinuation rates due to adverse events compared to SSRIs (OR=1.41,95% CI=1.10-1.79, P=0.006) 3
• 19% of venlafaxine patients discontinued treatment due to adverse events in Phase 2 and 3 studies 2
• Sertraline was associated with lower burden of moderate to severe discontinuation symptoms compared to venlafaxine 4

Serious and Unique Adverse Effects

Cardiovascular Risks

Venlafaxine carries cardiovascular risks that are uncommon with SSRIs 1:

• Dose-dependent blood pressure elevation, sometimes requiring discontinuation 1, 5
• Mean increases in diastolic blood pressure ranging from 0.7 to 2.5 mm Hg 2
• Increased pulse rate by approximately 3 beats per minute 2
• Risk of QT interval prolongation, potentially leading to torsades de pointes 5
• Venlafaxine is associated with more frequent fatal outcomes in overdose compared to SSRIs 5

Withdrawal/Discontinuation Syndrome

Venlafaxine causes more severe discontinuation symptoms than SSRIs 2, 4:

• Symptoms include agitation, dizziness, sensory disturbances (shock-like electrical sensations), nausea, anxiety, confusion, and headache 2
• These symptoms are dose-dependent and increase with longer treatment duration 2
• Gradual dose reduction is essential when discontinuing 2

Sexual Dysfunction

Sexual dysfunction rates are comparable between venlafaxine and SSRIs 1:

• Abnormal ejaculation/orgasm occurs in 12% of men on venlafaxine versus 2% on placebo 2
• Paroxetine (an SSRI) has higher rates of sexual dysfunction than other SSRIs and venlafaxine 1

Weight and Metabolic Effects

Venlafaxine causes less weight gain than some SSRIs 1:

• Mirtazapine and paroxetine result in higher weight gain than venlafaxine 1
• Venlafaxine is associated with dose-dependent weight loss in some patients 2

Clinical Implications

When to Avoid Venlafaxine

Given the higher adverse event burden, venlafaxine should be avoided in patients with 5, 6:

• Pre-existing hypertension or cardiovascular disease
• History of poor medication adherence (due to severe withdrawal symptoms)
• Concerns about overdose risk
• Pregnancy (second and third trimesters—increased risk of pre-eclampsia) 5

Tolerability Hierarchy

Among SNRIs, venlafaxine appears to be the least well-tolerated, combining serotonergic adverse effects with noradrenergic effects, particularly cardiovascular toxicity 6. Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity 6.

Common Pitfalls

• Do not abruptly discontinue venlafaxine—always taper gradually to minimize withdrawal symptoms 2
• Monitor blood pressure regularly, especially at doses above 225 mg/day where hypertension risk increases 2, 7
• Be aware that venlafaxine overdoses are more dangerous than SSRI overdoses, requiring smaller prescription quantities 5
• The short half-life (5 hours) of venlafaxine contributes to more severe withdrawal symptoms compared to longer half-life SSRIs 7